Neuroscience Education Institute

09/02/2026

When anxiety doesn’t look like anxiety, what should you look for? Generalized Anxiety Disorder (GAD) can present as insomnia, irritability, somatic complaints, difficulty concentrating, or symptoms that overlap with depression and everyday stress.

At the 2026 NEI Fall Congress, Jeffrey Strawn, MD, will explore how to recognize GAD more clearly and translate that diagnostic clarity into evidence-based treatment decisions.

From first-line treatment to partial response and emerging approaches, discover practical strategies you can bring back to your practice.

Use code STRAWN to save $50 on registration:

At the upcoming 2026 NEI Fall Congress, Dr. Jeffrey Strawn will take a practical look at how neurobiology, diagnostic clarity, and treatment evidence can help clinicians better recognize and manage generalized anxiety disorder.

09/01/2026

Could GLP-1 receptor agonists help address the mortality gap in serious mental illness? A large study by Dr. Roger McIntyre and colleagues found that GLP-1 RA initiation was associated with lower mortality and cardiovascular risk than sodium-glucose cotransporter-2 (SGLT2) inhibitor initiation in adults with SMI. Explore the findings, limitations, and clinical implications:

People with serious mental illness face a markedly shortened life expectancy, with cardiovascular disease driving much of the excess mortality. Could GLP-1 receptor agonists help improve survival? A new study compared mortality and cardiovascular outcomes following initiation of a GLP-1 receptor ago...

08/27/2026

Which older psychiatric therapies still deserve a place in your prescribing toolbox? At the upcoming 2026 NEI Fall Congress, Jonathan Meyer, MD, will examine contemporary evidence for rethinking legacy therapies and optimizing clozapine and lithium use. Gain practical strategies for recognizing treatment resistance earlier, managing adverse effects, improving monitoring, and navigating drug interactions.

Register today: https://nei.global/fall-reg

08/26/2026

Dr. Thomas Schwartz discusses common mistakes in psychopharmacology and how psychiatric clinicians can recognize and manage them. Tune in now

Dr. Thomas Schwartz discussing common mistakes in psychopharmacology and how psychiatric clinicians can recognize and manage them.

08/23/2026

Benzodiazepines are commonly prescribed to older adults for anxiety and insomnia despite risks including falls, motor vehicle crashes, and cognitive impairment. A recent study examined U.S. prescribing trends among adults aged 65 and older from 2015 to 2024, including overall and long-term use and dispensing in long-term care settings. Read more:

Benzodiazepines are commonly prescribed to older adults for anxiety and insomnia despite risks including falls, motor vehicle crashes, and cognitive impairment. A recent study examined U.S. prescribing trends among adults aged 65 and older from 2015 to 2024, including overall and long-term use and d...

08/22/2026

We’re live today! NEI Saturday Morning Live is starting soon. Log in now and join Dr. Thomas Schwartz for a morning focused on the evolving science and treatment of major depressive disorder, including emerging therapeutic targets, rapid-acting and adjunctive strategies, and practical insights for MDD care. Access the live program here:

Log in to NEI Saturday Morning Live on August 22, 2026, for a free, live CME/CE program featuring expert-led education, practical clinical insights, and an interactive Q&A. Access the event portal and join us live.

08/20/2026

Join Dr. Thomas Schwartz this Saturday, August 22, for NEI Saturday Morning Live and discover emerging approaches that go beyond traditional monoaminergic targets, including rapid-acting and adjunctive therapies that may help patients achieve meaningful improvement sooner. Register for free: https://nei.global/26sml-august22

08/20/2026

Lisa Tremayne, RN, PMH-C, CBCC spoke with attendees about managing patients with postpartum mood and anxiety disorder (PMAD). Even possible ways to prevent PMAD!

08/19/2026

Navigate the complexities of pediatric psychiatry with greater confidence. Join us November 4 for the 2026 NEI Fall Congress Child & Adolescent Psychiatry Academy and explore real-world approaches to autism and emotional dysregulation, pediatric anxiety, ADHD, disordered eating, and complex treatment decisions.
Learn from leading experts and leave with strategies you can put into practice.
Attend in person or online:

08/14/2026

A single-dose psychedelic treatment has met its primary endpoint and all key secondary endpoints in a Phase 3 study of adults with generalized anxiety disorder (GAD). The orally disintegrating formulation of lysergide (L*D) targets serotonin 5-HT2A receptors and is being investigated for its potential to provide sustained therapeutic effects after a single dose. Read more about the findings and what they could mean for the future of GAD treatment ➡️

Positive topline results from Voyage, a Phase 3 study evaluating a single 100 mcg dose of DT120 (lysergide) orally disintegrating tablet (ODT) in adults with generalized anxiety disorder (GAD).